Andrew J. Lee

Andrew J. Lee

Auto-generated profile, based on publicly available information

Andrew J. Lee

Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Science Immunology
Verified
Journal Article
Open access
PDF file
CKChang Gon Kim
Chang Gon Kim
MJMi Jang
Mi Jang
YKYoungun Kim
Youngun Kim
GLGalam Leem
Galam Leem
KKKyung Hwan Kim
Kyung Hwan Kim
ESEui-Cheol Shin
Eui-Cheol Shin
VEGF-A drives T cell exhaustion via TOX-dependent transcriptional programming in microsatellite stable colorectal cancers.

14 April 2023 in Science Advances
Verified
Journal Article
Open access
ALAndrew J. Lee
Andrew J. Lee
CKChangyoun Kim
Changyoun Kim
SPSeongwan Park
Seongwan Park
JJJaegeon Joo
Jaegeon Joo
BCBaekgyu Choi
Baekgyu Choi
IJInkyung Jung
Inkyung Jung
Parkinson’s disease (PD) is a progressive neurodegenerative disorder. However, cell type–dependent transcriptional regulatory programs responsible for PD pathogenesis remain elusive. Here, we establish transcriptomic and epigenomic landscapes of the substantia nigra by profiling 113,207 nuclei obtained from healthy controls and patients with PD. Our multiomics data integration provides cell type annotation of 128,724 cis-regulatory elements (cREs) and uncovers cell type–specific dysregulations in cREs with a strong transcriptional influence on genes implicated in PD. The establishment of high-resolution three-dimensional chromatin contact maps identifies 656 target genes of dysregulated cREs and genetic risk loci, uncovering both potential and known PD risk genes. Notably, these candidate genes exhibit modular gene expression patterns with unique molecular signatures in distinct cell types, highlighting altered molecular mechanisms in dopaminergic neurons and glial cells including oligodendrocytes and microglia. Together, our single-cell transcriptome and epigenome reveal cell type–specific disruption in transcriptional regulations related to PD.

1 December 2020 in Molecules and Cells
Verified
Journal Article
Open access
PDF file
WCWon-Young Choi
Won-Young Choi
JHJI HYUN HWANG
JI HYUN HWANG
ACAnn-Na Cho
Ann-Na Cho
ALAndrew J. Lee
Andrew J. Lee
IJInkyung Jung
Inkyung Jung
YKYoung-Joon Kim
Young-Joon Kim
Won-Young Choi, Ji-Hyun Hwang, Ann-Na Cho, Andrew J. Lee, Inkyung Jung, Seung-Woo Cho, Lark Kyun Kim, and Young-Joon Kim. Mol. Cells 2020;43:1011-22. https://doi.org/10.14348/molcells.2020.0207

12 November 2021 in Molecules and Cells
Verified
Journal Article
Open access
PDF file
SHSungwook Han
Sungwook Han
HLHosuk Lee
Hosuk Lee
ALAndrew J. Lee
Andrew J. Lee
SKSeung-Kyoon Kim
Seung-Kyoon Kim
IJInkyung Jung
Inkyung Jung
DLDaeyoup Lee
Daeyoup Lee
Sungwook Han, Hosuk Lee, Andrew J. Lee, Seung-Kyoon Kim, Inkyung Jung, Gou Young Koh, Tae-Kyung Kim, and Daeyoup Lee. Mol. Cells 2021;44:805-29. https://doi.org/10.14348/molcells.2021.0224

1 January 2026 in Science
Verified
Journal Article
Closed access
GAGaurav Agarwal
Gaurav Agarwal
MAMateusz Antoszewski
Mateusz Antoszewski
XXXueqin Xie
Xueqin Xie
YPYash Pershad
Yash Pershad
UAUma P. Arora
Uma P. Arora
VSVijay G. Sankaran
Vijay G. Sankaran
Somatic mutations that increase the fitness of hematopoietic stem cells (HSCs) drive their expansion in clonal hematopoiesis (CH) and predispose individuals to blood cancers. Population variation in the growth rate and potential of mutant clones suggests that genetic factors may confer resilience against CH. Here, we identified a noncoding regulatory variant, rs17834140-T, that protects against CH and myeloid malignancies by selectively down-regulating the RNA-binding protein MSI2 in HSCs. By modeling variant effects and mapping MSI2 binding targets, we uncovered an RNA network that maintains human HSCs and influences CH risk. Variant rs17834140-T was associated with slower CH expansion, and stem cell MSI2 levels modified ASXL1 -mutant HSC clonal dominance. These findings leverage natural resilience to illuminate posttranscriptional regulation in human HSCs, suggesting that inhibition of MSI2 or its targets could be rational strategies for blood cancer prevention.

13 November 2025 in Cancer Immunology Research
Verified
Journal Article
Open access
TNTruc Do Thanh Nguyen
Truc Do Thanh Nguyen
ALAndrew J. Lee
Andrew J. Lee
HPHyun Jung Park
Hyun Jung Park
NSNameeta Shah
Nameeta Shah
BMBayrta Mandzhieva
Bayrta Mandzhieva
WPWoong-Yang Park
Woong-Yang Park
Tumor-associated macrophages (TAM) play a crucial and important role in cancer dynamics by affecting homeostasis, immunosuppression, and angiogenesis within the tumor microenvironment. Using single-cell transcriptomics, we constructed a comprehensive atlas of myeloid cell populations across healthy and pan-cancer tissues that revealed heterogeneity. Our analysis suggested that TAMs may arise from two distinct origins: C1QC+ TAMs, which likely are derived from resident tissue macrophages, and SPP1+ TAMs and ISG15+ TAMs, which seem to originate from circulating monocytes. Regarding immature myeloid-derived suppressor cells (MDSC), we highlighted THBS1+ MDSCs and their descendants, SPP1+ TAMs, as key contributors to tumor progression, immunosuppression, and angiogenesis. We proposed a dichotomous model for TAMs, in which C1QC+ TAMs are associated with better patient outcomes, whereas the THBS1+ MDSC–SPP1+ TAM lineage correlates with poorer survival and unfavorable response to immunotherapy. This study offers insight into the complex interactions among monocyte–macrophage subtypes and sheds light on TAM heterogeneity and its implications for cancer progression and therapeutic strategies.